Trial
NCT00479167
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Rush University Medical Center
Collaborators
GlaxoSmithKline; Millennium Pharmaceuticals, Inc.
Condition
Follicular Lymphoma
Intervention
Bortezomib and Tositumomab I-131
Why stopped
Lack of accrual and interest in study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-04